Didanosine has been removed from the US market. No published information is available on the use of didanosine during breastfeeding. In the US and other countries where access to clean water and affordable replacement feeding are available, it is recommended that mothers living with HIV not breastfeed their infants to avoid postnatal transmission of HIV-1 infection. Didanosine is not recommended during breastfeeding.[1,2]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
AIDSinfo. Panel on treatment of pregnant women with HIV infection and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in transmission in the United States, 2018: Counseling and management of women living with HIV who breastfeed. https://aidsinfo.nih.gov/guidelines/html/3/perinatal/513/counseling-and-management-of-women-living-with-hiv-who-breastfeed.
2.
World Health Organization. HIV and infant feeding: Update. 2007. http://whqlibdoc.who.int/publications/2007/9789241595964_eng.pdf.
Substance Identification
Substance Name
Didanosine
CAS Registry Number
69655-05-6
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Infective Agents
Anti-HIV Agents
Antiviral Agents
Anti-Retroviral Agents
Reverse Transcriptase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.